Skip to main content
Clinical Trials/NCT01751672
NCT01751672
Completed
N/A

Integrating Substance Abuse Assessment & Intervention in Primary Care Settings

Treatment Research Institute3 sites in 1 country600 target enrollmentJune 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
Drug Use
Sponsor
Treatment Research Institute
Enrollment
600
Locations
3
Primary Endpoint
Change in Treatment Session Attendance from Baseline
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The purposes of this study are to: 1) implement a high fidelity Screening, Brief Intervention and Referral to Treatment (SBIRT) protocol with computerized screening technology into three primary care clinics in urban Philadelphia; 2) conduct a randomized controlled trial to determine if an expanded SBIRT (SBIRT+) will help patients attend more specialty substance abuse treatment sessions and reduce substance use compared to SBIRT; 3) conduct a process evaluation of SBIRT+ at the three collaborating clinics consisting of focus groups and structured interviews to assess implementation barriers and workforce attitudinal shifts; and 4) provide an excellent clinical research training environment for undergraduate and graduate students from Lincoln University.

Detailed Description

This project has several specific aims. First, investigators plan to implement a high fidelity Screening, Brief Intervention and Referral to Treatment (SBIRT) protocol with computerized screening technology into three primary care clinics in urban Philadelphia, and to train three Behavioral Health Consultants (BHCs) in an expanded brief intervention protocol (SBIRT+). Second, investigators will conduct a randomized controlled trial to address the following hypotheses: 1) patients assigned to SBIRT+ will attend more specialty substance abuse intervention and treatment sessions (excluding SBIRT+ sessions) over the 12 month follow-up than patients assigned to SBIRT; 2) patients assigned to SBIRT+ will demonstrate larger reductions in drug use by point prevalence urine samples and by reported days using over the 12-month follow-up compared to patients in SBIRT; 3) SBIRT+ will have positive net social benefits relative to SBIRT alone (i.e., will be cost-effective); 4) patients assigned to SBIRT+ will demonstrate improved medical, employment, legal, and psychiatric functioning, as well as reduced HIV risk over the 12-month follow-up compared to patients in SBIRT. Thirdly, investigators will also determine whether SBIRT and SBIRT+ are sustainable in primary care clinics as research funding for behavioral health consultants is phased out in Year 4 of the project. Investigators will also conduct a process evaluation of SBIRT+ at the three collaborating clinics consisting of focus groups and structured interviews to assess implementation barriers and workforce attitudinal shifts. This will inform methods to further disseminate SBIRT or SBIRT+, should the trial prove it is sustainable and cost-effective. Finally, investigators will provide an excellent clinical research training environment for undergraduate and graduate students from Lincoln University; this experience will balance hands-on clinical data collection and didactic training.

Registry
clinicaltrials.gov
Start Date
June 2012
End Date
May 2015
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Treatment Research Institute
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patient is 18 years or older
  • Alcohol and/or Drug screening score that indicates at least mild problem severity.

Exclusion Criteria

  • medical or psychiatric complications
  • substance use is mild enough that further intervention is not warranted
  • patient reports plans to leave the area within the next 12 months
  • patient is unable to provide valid informed consent

Outcomes

Primary Outcomes

Change in Treatment Session Attendance from Baseline

Time Frame: 0, 3, 6, 9, 12 months

Treatment sessions attended for alcohol or drug use issues over time.

Secondary Outcomes

  • Change in Cost-Effectiveness from Baseline(0, 3, 6, 9, 12 months)
  • Change in Urinalysis from Baseline(0, 3, 6, 9, 12 months)

Study Sites (3)

Loading locations...

Similar Trials